{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:50:55Z","timestamp":1761540655406},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1532\/ijh97.05049","type":"journal-article","created":{"date-parts":[[2005,10,4]],"date-time":"2005-10-04T21:02:44Z","timestamp":1128459764000},"page":"243-247","source":"Crossref","is-referenced-by-count":10,"title":["Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma"],"prefix":"10.1007","volume":"82","author":[{"given":"Naoya","family":"Ochiai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Fuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Hatsuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Ashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","first-page":"1045","volume":"43","author":"Ochiai, N","year":"2002","unstructured":"Ochiai N, Shimazaki C, Uchida R, et al. Thalidomide therapy in patients with refractory or relapsed multiple myeloma [in Japanese]. Rinsho Ketsueki. 2002;43:1045-1049.","journal-title":"Rinsho Ketsueki."},{"key":"E00002","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"Attal, M","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.","journal-title":"N Engl J Med."},{"key":"E00003","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","volume":"89","author":"Barlogie, B","year":"1997","unstructured":"Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.","journal-title":"Blood."},{"key":"E00004","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"Child, JA","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.","journal-title":"N Engl J Med."},{"key":"E00005","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","volume":"88","author":"Bjokstrand, B","year":"1996","unstructured":"Bjokstrand B, Ljungman P, Svensson H, et al.Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711-4718.","journal-title":"Blood."},{"key":"E00006","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","volume":"18","author":"Lokhorst, A","year":"2000","unstructured":"Lokhorst A, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3037.","journal-title":"J Clin Oncol."},{"key":"E00007","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","volume":"97","author":"Badros, A","year":"2001","unstructured":"Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97:2574-2579.","journal-title":"Blood."},{"key":"E00008","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","volume":"100","author":"Kroger, N","year":"2002","unstructured":"Kroger N, Schwerdtfeger R, Kiehl M, et al.Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100:755-760.","journal-title":"Blood."},{"key":"E00009","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1532\/IJH97.04174","volume":"81","author":"Shimazaki, C","year":"2005","unstructured":"Shimazaki C, Fujii H, Yoshida T, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group (JMSG). Int J Hematol. 2005;81:342-348.","journal-title":"Int J Hematol."},{"key":"E00010","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"Singhal, S","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341: 1565-1571.","journal-title":"N Engl J Med."},{"key":"E00011","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","volume":"109","author":"Juliusson, G","year":"2000","unstructured":"Juliusson G, Celsing F,Turesson I, Lenhoff S,Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89-96.","journal-title":"Br J Haematol."},{"key":"E00012","first-page":"404","volume":"86","author":"Hus, M","year":"2001","unstructured":"Hus M, Dmoszynska A, Soroka-Woitaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma. Haematologica. 2001;86:404-408.","journal-title":"Haematologica."},{"key":"E00013","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJM199911183412110","volume":"18","author":"Raje, N","year":"1999","unstructured":"Raje N, Anderson K. Thalidomide--a revival story. N Engl J Med. 1999;18:1606-1609.","journal-title":"N Engl J Med."},{"key":"E00014","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2002-03-0939","volume":"100","author":"Yaccoby, S","year":"2002","unstructured":"Yaccoby S, Johnson CL, Maahaffey SC, Wezeman MJ, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood. 2002;100:4162-4168.","journal-title":"Blood."},{"key":"E00015","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","volume":"96","author":"Hideshima, T","year":"2000","unstructured":"Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.","journal-title":"Blood."},{"key":"E00016","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","volume":"12","author":"Dimopoulos, MA","year":"2001","unstructured":"Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001;12:991-995.","journal-title":"Ann Oncol."},{"key":"E00017","first-page":"399","volume":"86","author":"Palumbo, A","year":"2001","unstructured":"Palumbo A, Giaccone L, Bertola A, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica. 2001;86:399-403.","journal-title":"Haematologica."},{"key":"E00018","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","volume":"121","author":"Anagnostopoulos, A","year":"2003","unstructured":"Anagnostopoulos A,Weber D, Rankin K, Delasalle K,Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003;121:768-771.","journal-title":"Br J Haematol."},{"key":"E00019","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","volume":"73","author":"Tosi, P","year":"2004","unstructured":"Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73:98-103.","journal-title":"Eur J Haematol."},{"key":"E00020","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.thj.6200403","volume":"5","author":"Palumbo, A","year":"2004","unstructured":"Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J. 2004;5:318-324.","journal-title":"Hematol J."},{"key":"E00021","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood.V98.13.3846","volume":"98","author":"Moehler, TM","year":"2001","unstructured":"Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood. 2001;98:3846-3848.","journal-title":"Blood."},{"key":"E00022","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF02983778","volume":"77","author":"Singhal, S","year":"2003","unstructured":"Singhal S, Mehta J. Novel therapies in multiple myeloma. Int J Hematol. 2003;77:226-231.","journal-title":"Int J Hematol."},{"key":"E00023","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"Berenson, JR","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488-493.","journal-title":"N Engl J Med."},{"key":"E00024","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(03)01076-3","volume":"4","author":"Ashcroft, AJ","year":"2003","unstructured":"Ashcroft AJ, Davies FE, Morgan GJ. An etiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol. 2003;4:284-292.","journal-title":"Lancet Oncol."},{"key":"E00025","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/028418600750063587","volume":"39","author":"Shipman, CM","year":"2000","unstructured":"Shipman CM, Rogers MJ,Vanderkerken K, et al. Bisphosphonates-- mechanisms of action in multiple myeloma. Acta Oncol. 2000;39: 829-835.","journal-title":"Acta Oncol."},{"key":"E00026","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","volume":"98","author":"Shipman, CM","year":"1997","unstructured":"Shipman CM, Rogers MJ, Apperley JF. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol. 1997;98:665-672.","journal-title":"Br J Haematol."},{"key":"E00027","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0145-2126(00)00087-4","volume":"25","author":"Takahashi, R","year":"2001","unstructured":"Takahashi R, Shimazaki C, Inaba T, et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res. 2001;25:77-83.","journal-title":"Leuk Res."},{"key":"E00028","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood.V81.10.2708.2708","volume":"81","author":"Corradini, P","year":"1993","unstructured":"Corradini P, Ladetto M,Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81:2708-2713.","journal-title":"Blood."},{"key":"E00029","first-page":"300","volume":"13","author":"Durie, BGM","year":"1986","unstructured":"Durie BGM. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300-309.","journal-title":"Semin Oncol."},{"key":"E00030","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"Durie, BGM","year":"1975","unstructured":"Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842-854.","journal-title":"Cancer."},{"key":"E00031","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"Blade, J","year":"1998","unstructured":"Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.","journal-title":"Br J Haematol."},{"key":"E00032","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","volume":"98","author":"Barlogie, B","year":"2001","unstructured":"Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-494.","journal-title":"Blood."},{"key":"E00033","first-page":"PI31","volume":"8","author":"Ciepluch, H","year":"2002","unstructured":"Ciepluch H, Braden W, Hellmann A. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. Med Sci Monit. 2002;8:PI31-PI36.","journal-title":"Med Sci Monit."}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.05049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T02:03:50Z","timestamp":1586484230000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.05049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,10,1]]}},"alternative-id":["8NH3L31NC2A6W57T"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.05049","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10,1]]}}}